Skip to main content
. Author manuscript; available in PMC: 2020 Jan 1.
Published in final edited form as: Breast Cancer Res Treat. 2018 Oct 13;173(2):289–299. doi: 10.1007/s10549-018-4989-2

Figure 4: Decreased MUC2 increases necrosis in PT12 tumors.

Figure 4:

PT12 xenograft tumors containing shRNA to MUC2 (shMUC2) versus wild type tumors (shCONT) (top panels) show decreased MUC2 expression by immunohistochemistry. Decreased Muc2 expression decreases proliferation by MCM2 staining (middle panels) and increase in necrosis as examined by mucicarmine staining (mucin pink, nuclei green, bottom panels). N = 8 tumors/group. Statistical significance determined using student’s t-test. Quantitation for each stain of the entire tumor is shown on the right. 20x images shown for MUC2 and MCM2; mucicarmine images shown at 7.5x to illustrate necrotic areas.